Loading provider…
Loading provider…
Neurology Physician in Los Angeles, CA
NPI: 1316097926Primary Employer
Option Care
optioncareltd.com
HQ Phone
Get MD Daniel's Phone Numberphone_androidMobile
Get MD Daniel's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMI State Medical License
2023 - 2026
CA State Medical License
1999 - 2024
CT State Medical License
2011 - 2015
CA State Medical License
Laval Univ
Medical School
Until 1994
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 17 | 17 |
Pathway and network-based analysis of genome-wide association studies in multiple sclerosis
The NAIMS cooperative pilot project: Design, implementation and future directions.
Authors: Pike, G B, De Stefano, N, Narayanan, S, Worsley, K J, Pelletier, D, Francis, G S, Antel, J P, Arnold, D L
Journal: Radiology
Lead Sponsor: Johns Hopkins University
Collaborators: University of Pennsylvania, University of Rochester, University of California, San Francisco, Yale University, Stanford University, Columbia University, The Cleveland Clinic, Swedish Medical Center, Oregon Health and Science University, University of Virginia, Washington University School of Medicine, Icahn School of Medicine at Mount Sinai, Anne Arundel Health System Research Institute, University of Massachusetts, Worcester, Dignity Health
Intervention / Treatment: DRUG: Vitamin D3
Lead Sponsor: Genzyme, a Sanofi Company
Intervention / Treatment: DRUG: alemtuzumab GZ402673
Lead Sponsor: Genzyme, a Sanofi Company
Collaborators: Bayer
Intervention / Treatment: BIOLOGICAL: Interferon beta-1a, BIOLOGICAL: Alemtuzumab 12 mg, BIOLOGICAL: Alemtuzumab 24 mg